Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Tivic Health Systems Inc (TIVC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/04/2025: TIVC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -46.17% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.68M USD | Price to earnings Ratio - | 1Y Target Price 210 |
Price to earnings Ratio - | 1Y Target Price 210 | ||
Volume (30-day avg) - | Beta 2 | 52 Weeks Range 2.43 - 16.08 | Updated Date 06/29/2025 |
52 Weeks Range 2.43 - 16.08 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.05 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2151.43% |
Management Effectiveness
Return on Assets (TTM) -100.63% | Return on Equity (TTM) -218.77% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1673245 | Price to Sales(TTM) 7.12 |
Enterprise Value 1673245 | Price to Sales(TTM) 7.12 | ||
Enterprise Value to Revenue 3.24 | Enterprise Value to EBITDA 0.16 | Shares Outstanding 965899 | Shares Floating 765790 |
Shares Outstanding 965899 | Shares Floating 765790 | ||
Percent Insiders 12.81 | Percent Institutions - |
Upturn AI SWOT
Tivic Health Systems Inc
Company Overview
History and Background
Tivic Health Systems Inc. focuses on bioelectronic medicine, developing non-invasive vagus nerve stimulation (nVNS) therapies. Founded in 2016, it has achieved milestones including FDA clearance for its ClearUP device and strategic partnerships.
Core Business Areas
- Sinus Pain and Congestion Relief: Development and sale of ClearUP, a medical device providing non-pharmaceutical relief from sinus pain and congestion using microcurrent waveforms.
Leadership and Structure
The leadership team includes Jennifer Ernst (CEO). The company has a typical corporate structure with departments dedicated to R&D, marketing, sales, and operations.
Top Products and Market Share
Key Offerings
- ClearUP: ClearUP is a non-invasive, over-the-counter device for treating sinus pain and congestion. The device has 166,000+ users. Main competitors include pharmaceutical companies offering decongestants and pain relievers, and other nasal irrigation or electronic stimulation devices. Market share data specific to ClearUP is not publicly available. Tivic Health derives the majority of its revenue from this product.
Market Dynamics
Industry Overview
The bioelectronic medicine market is growing, driven by increasing patient demand for non-pharmaceutical treatment options and technological advancements. Companies developing neuromodulation devices are gaining traction.
Positioning
Tivic Health is positioned as an innovator in non-invasive bioelectronic solutions for sinus pain and congestion. Its competitive advantage lies in its patented microcurrent technology and FDA-cleared ClearUP device.
Total Addressable Market (TAM)
The global sinusitis market is projected to reach multi billions in USD. Tivic Health's ClearUP targets a segment of this market focused on non-drug, non-invasive treatments. It is well-positioned in the non-invasive segment but market adoption relies on convincing users its product is the best non-invasive treatment.
Upturn SWOT Analysis
Strengths
- FDA-cleared ClearUP device
- Patented microcurrent technology
- Focus on non-pharmaceutical solutions
- Experienced management team
Weaknesses
- Limited product portfolio (reliance on ClearUP)
- Small market capitalization
- Limited financial resources
- Relatively new company
Opportunities
- Expansion into new indications (e.g., allergies, headaches)
- Partnerships with healthcare providers and retailers
- Increased awareness of bioelectronic medicine
- International expansion
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles for new products
- Reimbursement challenges from insurers
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- Johnson & Johnson (JNJ)
- Pfizer (PFE)
- GlaxoSmithKline (GSK)
Competitive Landscape
Tivic Health's advantage is its non-invasive device compared to pharmaceuticals, but it faces challenges in competing with the marketing budgets and established brands of major pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is difficult to assess without specific financial data.
Future Projections: Future projections are not available within this response.
Recent Initiatives: Recent initiatives include expanding ClearUP's market reach through online and retail channels, and exploring new indications for its technology.
Summary
Tivic Health is a small cap bioelectronic medicine company with an FDA cleared product, ClearUP, targeting sinus pain relief. The company's growth hinges on expanding ClearUP's market presence and diversifying its product portfolio. However, the company faces strong competition from larger pharmaceutical companies and relies significantly on a single product. Success will depend on demonstrating ClearUP's effectiveness and securing partnerships to broaden its reach.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market data is subject to change and may not be accurate. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tivic Health Systems Inc
Exchange NASDAQ | Headquaters Fremont, CA, United States | ||
IPO Launch date 2021-11-11 | Co-Founder, CEO & Director Ms. Jennifer Ernst | ||
Sector Healthcare | Industry Medical Devices | Full time employees 7 | Website https://tivichealth.com |
Full time employees 7 | Website https://tivichealth.com | ||
Tivic Health Systems, Inc., a health tech company, develops and commercializes bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for use in the treatment of sinus pain, pressure, and congestion. The company sells its products through online retailers and commercial distributors, as well as its own website. Its lead product candidate is Entolimod, a late-stage TLR5 agonist for use in the treatment of acute radiation syndrome. In addition, the company markets its commercial product under the ClearUP Sinus Pain Relief brand name. It also focusses on non-invasive vagus nerve stimulation. The company was incorporated in 2016 and is based in Fremont, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.